Eckert & Ziegler

(IN BRIEF) Eckert & Ziegler and Ariceum Therapeutics have signed a global supply agreement for critical medical radionuclides Actinium-225 (Ac-225) and Lutetium-177 (Lu-177). The radionuclides will be used in Ariceum’s lead radiopharmaceutical drug, satoreotide, targeting hard-to-treat cancers such as small … Read the full press release →

(IN BRIEF) The European Commission has approved Theralugand®, Eckert & Ziegler’s high-purity Lutetium-177 chloride, for routine clinical use across the European Economic Area. This approval allows its application in targeted cancer therapies, such as for neuroendocrine tumors and metastatic prostate … Read the full press release →

(IN BRIEF) Eckert & Ziegler has signed a multi-year agreement with Telix Pharmaceuticals to serve as the European contract manufacturing organization for Telix’s ProstACT GLOBAL Phase III study. The agreement includes supplying patients from Eckert & Ziegler’s Berlin facility and … Read the full press release →

(IN BRIEF) In early 2024, Europe’s medical and research communities announced major breakthroughs in cancer care, highlighting new treatments like AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan for lung and breast cancer, and AstraZeneca’s Tagrisso for EGFR-mutated lung cancer. Diagnostic advancements … Read the full press release →

(IN BRIEF) Eckert & Ziegler, in collaboration with Novartis Pharma K.K., is expanding Ga-68 labeled diagnostics in Japan through a clinical trial approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Utilizing Eckert & Ziegler’s GalliaPharm® generator, the trial … Read the full press release →